Regeneron's COURAGE trial: New approach to obesity treatment

CMS recently granted pass-through status to PET (positron emission tomography) product Gozellix from Australian drugmaker Telix Pharmaceuticals. This enables separate reimbursement for the radionuclide diagnostic agent under the Hospital Outpatient Prospective Payment System (HOPPS). 

Roche’s Elecsys pTau181 Test Obtains the US FDA’s Clearance to Rule Out Alzheimer’s Disease #roche #elecsyspTau181test #alzheimersdisease #phosphotau #medtech #negativepredictivevalue #invitrodiagnostic #amyloidpathology #usfda https://lnkd.in/gpagVS5r

"The more options that we have, the better we can really treat people in a personalised, effective and tolerable way, so oral GLP-1RAs are very exciting," says Dr Katherine Saunders, MD, co-founder of FlyteHealth As Eli Lilly and Company and Novo Nordisk near the end of the oral GLP-1RA development race, the editor of Clinical Trials Arena, Abigail Beaney speaks with Robert Barrie, editor of Pharmaceutical-Technology and Dr Saunders about how oral obesity medications will impact the market. You can listen to the full episode here: https://lnkd.in/ejmBnHrs

FlyteHealth's own Katherine Saunders, MD was recently featured on the Clinical Trials Arena podcast. On the promise of oral GLP-1RAs, Dr. Saunders shared: “The more options that we have, the better we can really treat people in a personalised, effective and tolerable way, so oral GLP-1RAs are very exciting.” This conversation explores how oral obesity medications could transform treatment options and reshape the market. 🎧 Listen to the full episode here: https://lnkd.in/ejmBnHrs

𝗘𝘃𝗼𝗹𝘃 𝗶𝗻𝘁𝗿𝗼𝗱𝘂𝗰𝗲𝘀 𝗳𝗶𝗿𝘀𝘁 𝗼𝗿𝗮𝗹 𝗚𝗟𝗣-𝟭 𝗯𝗶𝗼𝗺𝗶𝗺𝗲𝘁𝗶𝗰 𝗽𝗶𝗹𝗹 Evolv has launched what it calls the first oral GLP-1 biomimetic pill — offering a new, needle-free option for patients managing obesity and metabolic conditions. Designed to mimic the effects of injectable GLP-1 therapies, the innovation could help expand treatment accessibility and adherence across broader patient populations. Learn more: https://lnkd.in/gg89DHrj #Biotech #PharmaInnovation #ObesityCare #DrugDevelopment

#Peptides are transforming medicine with targeted treatments for metabolic disorders, injuries, and aesthetics, but traditional trials miss diverse patients and long-term data. RegenMed’s Circles platform collects high-quality, FDA-compliant #realworldevidence through physician and patient platforms without disrupting care. This data supports regulatory approval, payer decisions, and optimizes treatment protocols. 𝐊𝐞𝐲 𝐁𝐞𝐧𝐞𝐟𝐢𝐭𝐬: ✔️Comprehensive data from diverse patient populations including older adults and those with comorbidities ✔️Continuous insight into long-term safety, durability, and patient-reported outcomes ✔️Actionable evidence for clinicians to optimize treatment and for manufacturers to demonstrate value ✔️Enhanced regulatory and payer confidence for broader market access ✔️Improved personalized care for patients Embracing Circles-based #RWE closes the gap between controlled trials and real-world treatment, accelerating innovation and commercial success while delivering safer, effective therapies tailored for patient needs. Early adopters will lead the future of peptide therapeutics. For detailed insights, download the full white paper "Circles for the Evidence-Based Use of Peptides": https://hubs.li/Q03NfG-S0

GLP-1s are transforming obesity care, what started as a blood sugar tool is now a weight-loss powerhouse. Fascinating to see how GLP-1s are climbing the ranks fast. The shift from oncology dominance to metabolic therapies shaping pharma revenues shows how quickly patient needs and markets evolve. Behind record sales and double-digit weight loss, patient adherence could decide who wins the GLP-1 race. I pulled together a short visual deck capturing how obesity trends, drug efficacy, and patient behavior are shaping this $100B market. The next phase of GLP-1 innovation won’t be won in labs, it’ll be won in patient retention. What do you think is the biggest barrier for GLP-1 adoption? Cost, adherence, or safety?

In Europe, claims data only exists at the institutional level. See how one pharma company linked 394 physicians to high-volume obesity treatment centers in Germany to build their site selection strategy. Download the case study: https://hubs.la/Q03JhDqx0

𝗘𝘃𝗼𝗹𝘃 𝗶𝗻𝘁𝗿𝗼𝗱𝘂𝗰𝗲𝘀 𝗳𝗶𝗿𝘀𝘁 𝗼𝗿𝗮𝗹 𝗚𝗟𝗣-𝟭 𝗯𝗶𝗼𝗺𝗶𝗺𝗲𝘁𝗶𝗰 𝗽𝗶𝗹𝗹 Evolv has launched what it calls the first oral GLP-1 biomimetic pill — offering a new, needle-free option for patients managing obesity and metabolic conditions. Designed to mimic the effects of injectable GLP-1 therapies, the innovation could help expand treatment accessibility and adherence across broader patient populations. Learn more:https://lnkd.in/gaheDPvF #Biotech #PharmaInnovation #ObesityCare #DrugDevelopment

🚨 Big news as of September 22, 2025: Pfizer is acquiring Metsera 🚨 Metsera recently announced promising Phase 1 results for MET-233i (a once-monthly amylin analog). As a pharmacy student with interest in obesity and diabetes management, it’s exciting to see how monthly, multi-mechanism therapies could reshape future care! Deal highlights: 🔸 $47.50 per share in cash at closing ($4.9B) 🔸 Boards unanimously approved; closing expected Q4 2025 Why this matters scientifically: 🔹 GLP-1 therapies (like Wegovy, Zepbound) have transformed obesity care, but require weekly injections and can cause GI side effects. 🔹 Metsera’s MET-233i showed 8.4% placebo-adjusted weight loss in just 36 days with a half-life of around 19 days, enabling monthly dosing. 🔹 Amylin analogs act differently from GLP-1s - they slow gastric emptying, enhance satiety, and could deliver additive/synergistic weight loss when combined with GLP-1s. 🔹 Early data suggest a clean safety profile: only mild GI events, no serious AEs.